Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   12/09/2025
126,16 USD (-1,79%)
(-1,79%)   12/09/2025
Grafiek Jazz Pharmaceuticals plc Grafiek Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc in het nieuws

9 september 2025 · Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma · Persbericht

21 augustus 2025 · Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference · Persbericht

20 augustus 2025 · Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 · Persbericht

20 augustus 2025 · Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 · Persbericht

6 augustus 2025 · Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma · Persbericht

5 augustus 2025 · Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance · Persbericht

22 juli 2025 · Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 · Persbericht

10 juli 2025 · Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer · Persbericht

1 juli 2025 · Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer · Persbericht

10 juni 2025 · Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer · Persbericht

Profiel Jazz Pharmaceuticals plc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Mijn selecties